GENB Stock: Price, Earnings History and SEC Filings
Generate Biomedicines, Inc. (GENB) last traded at $14.46, down 8.31% on the latest session and down 3.7% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.52 against an analyst estimate of $-0.48, a miss of 8.3%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
GENB earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 6, 2026 | $-0.52 | $-0.48 | -8.33% |
| Mar 2026 | May 7, 2026 | $-1.07 | $-0.48 | -122.92% |
GENB beat the analyst EPS estimate in 0 of its last 2 reported quarters. Source: Nasdaq.
Latest SEC filings for GENB
- 8-K · Aug 26, 2026Regulation FD disclosure, Financial statements and exhibits
- 10-Q · Aug 6, 2026
- 8-K · Aug 6, 2026Results of operations, Financial statements and exhibits
- 10-Q · May 7, 2026
- 8-K · May 7, 2026Results of operations, Financial statements and exhibits
- 8-K · Mar 2, 2026Bylaw change, Financial statements and exhibits
- 424B4 · Feb 27, 2026
- S-1 · Feb 4, 2026
Insider filing activity
GENB insiders filed 1 Form 4 report in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
GENB news
- Generate Biomedicines (GENB) Stock Looks Fully Priced On Its 17% JumpOct 31, 2026 · finance.yahoo.com
- Anthropic Announced New Achievements in Drug Research and Lab Work. An Expert Says AI is 'Changing the Medical Field.'Oct 29, 2026 · ibtimes.com
- Generate Biomedicines to Participate in November Investor ConferencesOct 22, 2026 · finance.yahoo.com
About Generate Biomedicines, Inc.
Generate Biomedicines, Inc. (GENB) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in DE. Its fiscal year ends in December.